Abstract 5828
Background
The phase III international FOxTROT trial assessed the effectiveness of pre-operative chemotherapy in locally advanced colon cancer. Patients were randomised across 85 centres to pre- and post-operative FOLFOX-based chemotherapy (pre-op) or to post-operative FOLFOX chemotherapy alone (post-op) in a 2:1 ratio.
Methods
Central pathological review was performed on scanned H&E stained slides in 904 out of 1,052 cases (86%) to include reassessment of the core pathology endpoints and an additional assessment of novel prognostic and immunological markers according to trial arm.
Results
The pre-op group showed a lower pT stage (pT0-pT2 rate 18% vs 8%, p < 0.0001), lower pN stage (pN0 rate 64% vs. 52%, p = 0.0002), smaller tumour diameter (40mm vs. 51mm, p < 0.0001), and greater R0 rate (99% vs. 96%, p = 0.02). The pre-op group showed a lower rate of apical node metastases (3% vs. 8%, p = 0.002), extracapsular spread (8% vs. 19%, p < 0.0001), intramural venous invasion (20% vs. 33%, p < 0.0001), extramural venous invasion (35% vs. 44%, p = 0.004) and lymphatic invasion (46% vs. 55%, p = 0.002). The percentage of the patients with high-grade tumour budding was lower in pre-op group (5% vs. 14%, p < 0.0001). Significantly greater numbers of stromal tumour infiltrating lymphocytes (TILs) (14% vs. 9%, p < 0.0001) and eosinophils (6% vs. 3%, p < 0.0001) were observed in the pre-op group, however, intratumoural TILs were equivalent (5% vs. 5%, p = 0.63). Significantly lower numbers of neutrophils (5% vs. 10%, p < 0.0001) and reduced abscess formation (11% vs. 21%, p < 0.0001) was seen in the pre-op group. The average area of all uninvolved lymph nodes was smaller in the preoperative group as was the average tumour area in metastatic nodes.
Conclusions
Pre-op chemotherapy in locally advanced colon cancer is associated with a significant reduction in many high-risk pathological features and potential mechanisms of metastatic spread. There is also a clear effect on tumour immunology. The association with 2 year DFS is currently being performed and will be presented at the meeting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Birmingham.
Funding
Amgen.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1057 - TRIUMPH: Primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): A GOZILA Sub-study
Presenter: Yoshiaki Nakamura
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
4795 - Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
Presenter: John Strickler
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
2951 - Impact of clonality and DNA repair mutations on plasma tumor mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26
Presenter: Jonathan Loree
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
3298 - Early identification of treatment effect by methylated circulating tumor DNA in metastatic colorectal cancer
Presenter: Caroline Thomsen
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
5073 - Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer
Presenter: Elisa Fontana
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
2646 - Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first line (1L). PERSEIDA study
Presenter: Manuel Valladares-Ayerbes
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
3464 - BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine (C) Bevacizumab (B) plus Atezolizumab (A) or Placebo (P) in Refractory Metastatic Colorectal Cancer (mCRC): An ACCRU Network Study
Presenter: Niharika Mettu
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
3857 - Phase II Study of Pertuzumab and Trastuzumab-emtansine (T-DM1) in Patients with HER2-positive Metastatic Colorectal Cancer: the HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) Trial
Presenter: Andrea Sartore-Bianchi
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
5756 - Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): final analysis, tumor biomarkers and methylated ctDNA
Presenter: Filippo Pietrantonio
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
Poster Discussion – Gastrointestinal tumours, colorectal - Invited Discussant LBA35, LAB36, 526PD and 527PD
Presenter: Ramon Salazar
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast